ASTEC LIFESCIENCES LIMITED

Astec Lifesciences Ltd has announced that its Board of Directors will convene on October 26, 2026. The primary agenda for this meeting is to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half-year ended September 30, 2026. This approval will follow a review by the company's Audit Committee. The company has also made the intimation available on its website.

Astec Lifesciences Ltd has responded to a stock exchange query regarding a significant increase in trading volume. The company stated that it is conscious of its responsibility to disseminate price-sensitive information promptly and has been compliant with SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. Astec Lifesciences confirmed that there are no undisclosed developments requiring mandatory disclosure under LODR or the Prohibition of Insider Trading (PIT) Regulations, 2015. They assured continued compliance with all applicable regulations.

Astec Lifesciences Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ending September 30, 2026. All officers, designated employees, including directors and auditors, are prohibited from trading in the company's equity shares during this period.

Astec Lifesciences Ltd has responded to a stock exchange inquiry regarding a significant increase in trading volume. The company confirmed its compliance with SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, and the Prohibition of Insider Trading (PIT) Regulations, 2015. They stated that all material information impacting share price has been promptly disseminated and that no undisclosed material developments requiring mandatory disclosure have occurred.

Astec Lifesciences Ltd has responded to a BSE email dated September 10, 2026, regarding a significant increase in the volume of its securities. The company affirmed its commitment to timely dissemination of price-sensitive information as per SEBI Listing Regulations. Astec Lifesciences confirmed compliance with disclosure requirements under the Listing Regulations and the PIT Regulations, stating there are no undisclosed material developments requiring mandatory disclosure. The company assured continued adherence to regulatory obligations and appropriate disclosures as and when required.

Astec Lifesciences Ltd has responded to a stock exchange query regarding a significant increase in trading volume. The company stated that it is conscious of its responsibility to disseminate price-sensitive information promptly and has been compliant with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Astec Lifesciences confirmed that there are no undisclosed developments requiring mandatory disclosure under the Listing Regulations or the Prohibition of Insider Trading Regulations, 2015. They assured continued compliance with all applicable regulations.

Astec Lifesciences Limited successfully conducted its 32nd Annual General Meeting (AGM) on July 31, 2026, via Video Conferencing. The meeting, held in compliance with MCA and SEBI regulations, saw the adoption of the Annual Report for the Financial Year 2025-26 and the approval of various resolutions. The company provided remote e-voting facilities and allowed e-voting during the meeting. The results of the voting will be declared within two working days. Key attendees included the Board of Directors, statutory auditors B S R & Co. LLP, and secretarial auditors BNP & Associates.

Astec Lifesciences Limited successfully conducted its 32nd Annual General Meeting (AGM) on July 31, 2026, via Video Conferencing. The meeting, held in compliance with MCA and SEBI regulations, saw the adoption of the Annual Report for the Financial Year 2025-26. Shareholders also voted on resolutions including the adoption of financial statements and the re-appointment of a director. The company provided remote e-voting facilities and allowed e-voting during the AGM. The proceedings included a welcome by the Company Secretary, a speech by the Chairperson, and attendance by directors and auditors.

Astec LifeSciences Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a consolidated total income of ₹84.3 crore, a decrease from ₹91.6 crore in the same period last year. However, Astec achieved EBITDA breakeven at ₹0.1 crore, a significant improvement from an EBITDA loss of ₹-10.5 crore in Q1 FY26. The net loss after tax narrowed to ₹-18.7 crore from ₹-33.0 crore year-on-year. Revenue from Enterprise Products grew by 41.6% to ₹51.8 crore, while revenue from Contract Manufacturing & New Products declined by 41.8% to ₹31.8 crore. The Chairperson attributed the EBITDA improvement to a favorable product mix, improved margins, and enhanced capacity utilization, despite the overall revenue dip.

Astec Lifesciences Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated results as per Indian Accounting Standards (IND AS). The company also noted the Limited Review Reports from its Statutory Auditors, which carried an unmodified opinion on the financial results.